Guardant Health (GH) announced a multi-year strategic collaboration with Nuvalent (NUVL) to support the development and potential commercialization of Nuvalent’s oncology pipeline using the tissue and liquid offerings of the Guardant Infinity platform.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health: Buy Rating Reiterated as Management Changes Seen as Non-Disruptive and $135 Price Target Maintained on Multiple Growth Catalysts
- Overhang should lift for Guardant after AstraZeneca AdCom, says Leerink
- Guardant falls after FDA briefing documents for camizestrant
- Guardant Health Announces Resignation of Chief Medical Officer
- Guardant Health Chief Medical Officer resigns effective May 8